Generics: Upadacitinib Patent Showdown in India Key Update: Delhi High Court orders the Indian Patent Office to conclude all oppositions on AbbVies upadacitinib API patent (IN4759/DELNP/2012) by 30 April 2026
Through the 1980s and 1990s, research expanded to cover wound healing, skin remodeling, and collagen synthesis
Just be sure it doesnt overlap with your morning levothyroxine
Diabetes Metab Syndr 16(6):102511 Yabe D, Seino Y (2011) Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference
SURMOUNT-5: The head-to-head trial Published in the New England Journal of Medicine in 2025, SURMOUNT-5 was the first randomised trial to directly compare tirzepatide (Mounjaro) with semaglutide (Wegovy) at equivalent maximum doses in adults with obesity without type 2 diabetes
Albiglutide is also a once-weekly GLP-1RA consisting of two copies of a 30 amino acid sequence of modified human GLP-1 (replacement of alanine with glycine at position 8) fused with human albumin [22]